Blinatumomab: A novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 10, 2011, Pages 776-777

  Advani, Anjali S ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHILL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MONITORING; PROGNOSIS; TREATMENT RESPONSE;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; T-LYMPHOCYTES;

EID: 80155194918     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-2498.
2. Topp MS, Zugmaier G, Gokbuget N, et al. Report of a phase II trial of singleagent BiTE antibody blinatumomab in patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 840.
3. ClinicalTrials.gov. An open-label, multi-center phase I study to investigate the tolerability and safety of a continuous infusion of the bispecific T-cell engager MT103 in patients with relapsed non-Hodgkin's lymphoma (NHL). Identifier: NCT00274742. http://clinicaltrials.gov/ct2/show/NCT00274742.
4. ClinicalTrials.gov. Confirmatory phase II study of blinatumomab (MT103) in patients with minimal residual disease of B-precursor ALL (BLAST). Identifier: NCT01207388. http://clinicaltrials.gov/ct2/show/NCT01207388.